ARTS WAY MANUFACTURING CO INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARTS WAY MANUFACTURING CO INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $22.98M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $24.50M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $30.28M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $25.65M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $24.97M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $22.41M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $22.89M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $19.73M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $20.72M | Feb 5, 2019 |
| FY2012 | Nov 30, 2012 | $36.46M | Feb 27, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Nov 30, 2017 | $20.72M | Feb 7, 2018 |
| FY2017 | Nov 30, 2016 | $21.56M | Feb 7, 2018 |
| FY2016 | Nov 30, 2015 | $26.33M | Feb 2, 2017 |
| FY2015 | Nov 30, 2014 | $36.17M | Feb 3, 2016 |
| FY2014 | Nov 30, 2013 | $34.23M | Mar 17, 2015 |
| FY2013 | Nov 30, 2012 | $36.46M | Feb 26, 2014 |
| FY2012 | Nov 30, 2011 | $27.62M | Feb 27, 2013 |
| FY2011 | Nov 30, 2010 | $28.95M | Feb 24, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $6.27M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $7.31M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $8.58M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $6.94M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $6.60M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $2.40M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $3.93M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $3.51M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $4.08M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $5.32M | Feb 7, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $1.03M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $307.4K | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $267.0K | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $97.8K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $212.6K | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | ($2.10M) | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | ($1.42M) | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | ($3.39M) | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | ($1.64M) | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | ($821.3K) | Feb 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $289.5K | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $460.7K | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $1.53M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $604.7K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $523.4K | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | ($3.91M) | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | ($1.50M) | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | ($3.10M) | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | ($1.72M) | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | ($431.4K) | Feb 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $228.0K | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $216.0K | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $204.0K | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $193.0K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $152.0K | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $199.0K | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $149.0K | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $178.0K | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $183.0K | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $140.0K | Feb 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($904.1K) | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $2.63M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | ($55.2K) | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $951.7K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | ($985.9K) | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | ($856.3K) | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $807.8K | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | ($1.12M) | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $747.4K | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $2.38M | Feb 7, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $627.6K | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $724.7K | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $841.8K | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $1.67M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $620.3K | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $693.4K | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $447.0K | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $434.5K | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $513.6K | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $274.1K | Feb 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $22.48M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $21.24M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $24.40M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $23.95M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $20.85M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $18.80M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $19.35M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $21.33M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $24.38M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $27.24M | Feb 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $9.17M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $9.15M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $12.76M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $12.80M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $10.50M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $8.90M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $7.55M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $8.29M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $8.39M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $9.77M | Feb 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $13.31M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $12.09M | Feb 12, 2026 |
| FY2025 | Nov 30, 2023 | $11.64M | Feb 12, 2026 |
| FY2024 | Nov 30, 2022 | $11.15M | Feb 18, 2025 |
| FY2023 | Nov 30, 2021 | $10.35M | Feb 28, 2024 |
| FY2022 | Nov 30, 2020 | $9.91M | Feb 16, 2023 |
| FY2021 | Nov 30, 2019 | $11.79M | Feb 17, 2022 |
| FY2020 | Nov 30, 2018 | $13.04M | Feb 9, 2021 |
| FY2019 | Nov 30, 2017 | $15.99M | Feb 6, 2020 |
| FY2018 | Nov 30, 2016 | $17.48M | Feb 5, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Nov 30, 2017 | $375.0K | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $375.0K | Feb 7, 2018 |
| FY2016 | Nov 30, 2015 | $375.0K | Feb 2, 2017 |
| FY2015 | Nov 30, 2014 | $993.7K | Feb 3, 2016 |
| FY2014 | Nov 30, 2013 | $993.7K | Mar 17, 2015 |
| FY2013 | Nov 30, 2012 | $993.7K | Feb 26, 2014 |
| FY2012 | Nov 30, 2011 | $375.0K | Feb 27, 2013 |
| FY2011 | Nov 30, 2010 | $375.0K | Feb 24, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $8.36M | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $7.33M | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $7.02M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $6.75M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $6.66M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $6.44M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $8.55M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $9.97M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $13.35M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $14.99M | Feb 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $4.8K | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | $1.9K | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | $4.0K | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $5.1K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $2.7K | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $2.7K | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $3.1K | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $3.5K | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $212.4K | Feb 5, 2019 |
| FY2018 | Nov 30, 2016 | $1.06M | Feb 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $2.49M | Feb 12, 2026 |
| FY2024 | Nov 30, 2024 | $2.09M | Feb 18, 2025 |
| FY2024 | Nov 30, 2023 | $2.74M | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | $2.84M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $2.73M | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | $2.81M | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | $2.44M | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | $2.75M | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | $3.57M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | $3.91M | Feb 7, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | 0 | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | 0 | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | 0 | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | 0 | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | 0 | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | 0 | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | 0 | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | 0 | Feb 7, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Nov 30, 2024 | 0 | Feb 12, 2026 |
| FY2024 | Nov 30, 2023 | 0 | Feb 18, 2025 |
| FY2023 | Nov 30, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | 0 | Feb 16, 2023 |
| FY2021 | Nov 30, 2020 | 0 | Feb 17, 2022 |
| FY2020 | Nov 30, 2019 | 0 | Feb 9, 2021 |
| FY2019 | Nov 30, 2018 | 0 | Feb 6, 2020 |
| FY2018 | Nov 30, 2017 | 0 | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | 0 | Feb 7, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Nov 30, 2018 | 4.23M | Feb 5, 2019 |
| FY2018 | Nov 30, 2017 | 4.16M | Feb 5, 2019 |
| FY2017 | Nov 30, 2016 | 4.11M | Feb 7, 2018 |
| FY2016 | Nov 30, 2015 | 4.06M | Feb 2, 2017 |
| FY2015 | Nov 30, 2014 | 4.05M | Feb 3, 2016 |
| FY2014 | Nov 30, 2013 | 4.05M | Mar 17, 2015 |
| FY2013 | Nov 30, 2012 | 4.04M | Feb 26, 2014 |
| FY2012 | Nov 30, 2011 | 4.03M | Feb 27, 2013 |
| FY2011 | Nov 30, 2010 | 4.01M | Feb 24, 2012 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Nov 30, 2015 | $202.4K | Feb 3, 2016 |
| FY2013 | Nov 30, 2013 | $404.7K | Feb 26, 2014 |
| FY2012 | Nov 30, 2012 | $403.6K | Feb 27, 2013 |
| FY2011 | Nov 30, 2011 | $241.6K | Feb 24, 2012 |
| FY2011 | Nov 30, 2010 | $240.0K | Feb 24, 2012 |